Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA.

Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B.

Mol Endocrinol. 2009 Aug;23(8):1203-14. doi: 10.1210/me.2008-0470. Epub 2009 Apr 23.

2.

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.

Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B.

Cancer Res. 2014 May 15;74(10):2857-68. doi: 10.1158/0008-5472.CAN-13-2003. Epub 2014 Mar 19.

3.

General transcription factor IIA-gamma increases osteoblast-specific osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2.

Yu S, Jiang Y, Galson DL, Luo M, Lai Y, Lu Y, Ouyang HJ, Zhang J, Xiao G.

J Biol Chem. 2008 Feb 29;283(9):5542-53. doi: 10.1074/jbc.M705653200. Epub 2008 Jan 2.

4.
5.

Negative modulation of androgen receptor transcriptional activity by Daxx.

Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G, Kung HJ, Shih HM.

Mol Cell Biol. 2004 Dec;24(24):10529-41.

6.

Bone-specific transcription factor Runx2 interacts with the 1alpha,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells.

Paredes R, Arriagada G, Cruzat F, Villagra A, Olate J, Zaidi K, van Wijnen A, Lian JB, Stein GS, Stein JL, Montecino M.

Mol Cell Biol. 2004 Oct;24(20):8847-61.

7.

Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.

Baniwal SK, Little GH, Chimge NO, Frenkel B.

J Cell Physiol. 2012 May;227(5):2276-82. doi: 10.1002/jcp.22966.

8.

Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization.

Kawate H, Wu Y, Ohnaka K, Takayanagi R.

J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):46-56. Epub 2007 May 17.

PMID:
17627815
9.

Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer.

Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B.

Endocrinology. 2008 Dec;149(12):5984-95. doi: 10.1210/en.2008-0680. Epub 2008 Aug 28.

10.
11.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

12.

Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.

Carcinogenesis. 2008 Sep;29(9):1725-33. doi: 10.1093/carcin/bgn117. Epub 2008 May 16.

13.

The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Biochem. 2010 Mar 1;109(4):828-37. doi: 10.1002/jcb.22463.

14.

Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3beta.

Ziros PG, Georgakopoulos T, Habeos I, Basdra EK, Papavassiliou AG.

J Bone Miner Res. 2004 Nov;19(11):1892-904. Epub 2004 Jul 7.

15.

Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.

Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang Y, He D, Chang C.

Carcinogenesis. 2013 Feb;34(2):257-67. doi: 10.1093/carcin/bgs337. Epub 2012 Oct 26.

16.

Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.

Suh JH, Gong EY, Kim JB, Lee IK, Choi HS, Lee K.

Mol Cancer Res. 2008 Feb;6(2):314-24. doi: 10.1158/1541-7786.MCR-07-0354. Epub 2008 Feb 1.

17.

The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells.

Song CH, Lee HJ, Park E, Lee K.

PLoS One. 2012;7(11):e49026. doi: 10.1371/journal.pone.0049026. Epub 2012 Nov 7.

18.

Nrf2 negatively regulates osteoblast differentiation via interfering with Runx2-dependent transcriptional activation.

Hinoi E, Fujimori S, Wang L, Hojo H, Uno K, Yoneda Y.

J Biol Chem. 2006 Jun 30;281(26):18015-24. Epub 2006 Apr 12.

19.

The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.

Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP, Bai C.

Mol Endocrinol. 2004 Aug;18(8):2011-23. Epub 2004 May 6.

PMID:
15131260
20.

Supplemental Content

Support Center